Trials / Completed
CompletedNCT02295969
Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
An Observational Study of ORALAIR® (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 307 (actual)
- Sponsor
- Stallergenes Greer · Industry
- Sex
- All
- Age
- 5 Years – 9 Years
- Healthy volunteers
- Not accepted
Summary
Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.
Detailed description
The purpose of this study is to further describe the safety and tolerability of ORALAIR tablets in children 5 to 9 years of age with grass-pollen-induced allergic rhinitis with or without conjunctivitis. Patients are followed for safety and tolerability during the first 30 treatment days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oralair | Observational study, Oralair is used as prescribed by the prescriber phycisian. |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2017-07-03
- Completion
- 2017-07-03
- First posted
- 2014-11-20
- Last updated
- 2017-07-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02295969. Inclusion in this directory is not an endorsement.